delegate,WallStreetUniverse

[Dana Kramer]

Adriana Combs,

Genex Pharmaceutical, Inc. (OTCBB: GENX)

Chinese Biotech Company Producing Reconstituted Bone Xenograft (RBX) Signs Letter of Intent to Acquire Vitamin B1 Manufacturer that Posted US $16 MILLI0N in Revenue for Fiscal 2003 and Net Income of Approximately US $3 MILLI0N

The 10Q which was released on August 16th showed revenues of $525,750 for the quarter ending June 30th. vs. $98,763 for the same period a year ago. Net Income three months ended June 30, 2004: $151,904 vs. a loss of $3,929 for the same period a year ago.

About Genex Pharmaceutical, Inc.

Product Distributed to 400 Hospitals in 22 Provinces

Genex Pharmaceutical, Inc. is a biomedical technology company with distinctive proprietary technology for an orthopedic device that treats bone-related injuries. Headquartered in Tianjin, China, the Company manufactures and distributes Reconstituted Bone Xenograft (RBX), to 400 hospitals in 22 provinces throughout mainland China. RBX is approved by the State Food and Drug Administration (SFDA) in China (the Chinese government agency that regulates drugs and medical devices). RBX offers a modern alternative to traditional methods of treating orthopedic injuries. (Source: News Release 7/27/04)

Recent Press Release Headlines:

The Good News Keeps on Coming for GENX - Go Read the Full Stories!

*Genex Pharmaceutical Adopts New Proprietary Technology, Substantially Reduces Manufacturing Costs, Sees Positive Impact to Earnings.

*Genex Pharmaceutical Signs Letter of Intent to Acquire One of the World's Largest Producers of Vitamin B1.

*Genex Pharmaceutical Sees Strong Earnings Growth for 2004 and 2005.

*Genex Pharmaceutical 2nd Quarter Revenue Up 432%, Gross PR0FIT Up 380%, Net INC0ME Soars, Sees Continued Earnings Momentum for Remainder of 2004.

Strongly Consider The Following:

Many investors (some of them are now called millionaires), see the potential for emerging companies before the numbers grab Wall Street's Attention. That 's how the big money is made! Were they just lucky? I don't think so- and as an investor, I suspect you don't either. The truth is, they see something the average investor doesn't- Hidden Profit Potential- make that Enormous Profit Potential And the rest is history- Very Rich History.

Read the announcements GENX has made. Look at the Company. Read the Filings. Do you see the Potential for Explosive Growth? You may agree that's where the big money is made - Finding small gems already top line producing and poised for massive growth. Consider GENX for your portfolio today. Good Luck and Successful Investing.

DIS-CLAIMER: Information within this ema-il contains F0RWARD looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as projects , foresee, expects, will, anticipates, estimates, believes, understands or that by statements indicating certain actions may, could, or might occur. As with many micro-cap stocks, today's company has additional risk factors worth noting. Those factors include: a limited operating history: the company advancing cash to related parties and a shareholder on an unsecured basis: one vendor, a related party through a majority stockholder, supplies ninety-seven percent of the company's raw materials: reliance on two customers for over fifty percent of their business and numerous related party transactions and the need to raise capital.These risk factors and others are fully detailed in the company's SEC filings and company press releases. We urge you to read them before you invest. The Publisher of this letter does not represent that the information contained in this message states all material facts or does not omit a material fact necessary to make the statements therein not misleading.All information provided within this ema-il pertaining to investing, ST0CKS or securities must be understood as information provided and not investment advice. The Publisher of this letter advises all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this ema-il. None of the material within this report shall be construed as any kind of investment advice or solicitation. Many of these companies are on the verge of bankruptcy. You can lose all your money by investing in this stock. The Publisher of this letter is not a registered investment ADVIS0R. Subscribers should not view information herein as legal, tax, accounting or investment advice. Any reference to past performance(s) of companies are specially selected to be referenced based on the favorable performance of these companies. You would need perfect timing to acheive the results in the examples given. There can be no assurance of that happening.Remember, as always, past performance is ne-ver indicative of future results and a thorough due diligence effort, including a review of a company's filings, should be completed prior to investing. In compliance with the Securities Act of 1933, Section17(b),The Publisher of this letter discloses the receipt of thirty three thousand dollars from a third party, not an officer, director or affiliate shareholder for the circulation of this report. Be aware of an inherent conflict of interest resulting from such compensation due to the fact that this is a paid adver-tisement and is not without bias. All factual information in this report was gathered from public sources, including but not limited to Company Websites, SEC Filings and Company Press Releases. The Publisher of this letter believes this information to be reliable but can make no guar-antee as to its accuracy or completeness. Use of the material within this ema-il constitutes your acceptance of these terms.

jazzy snail armour rockaway complimentary craft wholesome hinman medlar affect skopje epa bronchiolar anteater cryptogram eightieth h's hexagonal satyr lobotomy wastrel snippet cockcrow earl clinician ,curl ekstrom require chloroplast thunderflower deceive advocacy connecticut cholera allison heine geminate respiratory janus empiric frivolous mightn't filthy anion figure inertia djakarta art fifteenth shipyard gully rut precedent turbidity asymptote defray swastika songful placid .